<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>2273</number>
    <updateDate>2023-01-11T16:03:29Z</updateDate>
    <updateDateIncludingText>2023-01-11T16:03:29Z</updateDateIncludingText>
    <originChamber>House</originChamber>
    <originChamberCode>H</originChamberCode>
    <type>HR</type>
    <introducedDate>2007-05-10</introducedDate>
    <congress>110</congress>
    <committees>
      <item>
        <systemCode>hsif00</systemCode>
        <name>Energy and Commerce Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <subcommittees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
            <activities>
              <item>
                <name>Referred to</name>
                <date>2007-05-10T18:36:06Z</date>
              </item>
            </activities>
          </item>
        </subcommittees>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2007-05-10T13:02:10Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <actions>
      <item>
        <actionDate>2007-05-10</actionDate>
        <committees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2007-05-10</actionDate>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2007-05-10</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2007-05-10</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>H000627</bioguideId>
        <fullName>Rep. Hinchey, Maurice D. [D-NY-22]</fullName>
        <firstName>MAURICE</firstName>
        <lastName>HINCHEY</lastName>
        <party>D</party>
        <state>NY</state>
        <middleName>D.</middleName>
        <district>22</district>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>S001045</bioguideId>
        <fullName>Rep. Stupak, Bart [D-MI-1]</fullName>
        <firstName>BART</firstName>
        <lastName>STUPAK</lastName>
        <party>D</party>
        <state>MI</state>
        <district>1</district>
        <sponsorshipDate>2007-05-10</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>G000551</bioguideId>
        <fullName>Rep. Grijalva, Raúl M. [D-AZ-7]</fullName>
        <firstName>Raúl</firstName>
        <lastName>Grijalva</lastName>
        <party>D</party>
        <state>AZ</state>
        <middleName>M.</middleName>
        <district>7</district>
        <sponsorshipDate>2007-05-10</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Administrative fees</name>
        </item>
        <item>
          <name>Animals</name>
        </item>
        <item>
          <name>Clinical trials</name>
        </item>
        <item>
          <name>Commerce</name>
        </item>
        <item>
          <name>Communication in medicine</name>
        </item>
        <item>
          <name>Conflict of interests</name>
        </item>
        <item>
          <name>Consumer education</name>
        </item>
        <item>
          <name>Consumer protection</name>
        </item>
        <item>
          <name>Data banks</name>
        </item>
        <item>
          <name>Department of Health and Human Services</name>
        </item>
        <item>
          <name>Drug advertising</name>
        </item>
        <item>
          <name>Drug approvals</name>
        </item>
        <item>
          <name>Drug industry</name>
        </item>
        <item>
          <name>Drugs</name>
        </item>
        <item>
          <name>Economics and Public Finance</name>
        </item>
        <item>
          <name>Executive reorganization</name>
        </item>
        <item>
          <name>Federal advisory bodies</name>
        </item>
        <item>
          <name>Federal-state relations</name>
        </item>
        <item>
          <name>Fines (Penalties)</name>
        </item>
        <item>
          <name>Food and Drug Administration (FDA)</name>
        </item>
        <item>
          <name>Government Operations and Politics</name>
        </item>
        <item>
          <name>Government and business</name>
        </item>
        <item>
          <name>Government ethics</name>
        </item>
        <item>
          <name>Government publicity</name>
        </item>
        <item>
          <name>Health education</name>
        </item>
        <item>
          <name>Health information systems</name>
        </item>
        <item>
          <name>Informed consent (Medical law)</name>
        </item>
        <item>
          <name>Labeling</name>
        </item>
        <item>
          <name>Law</name>
        </item>
        <item>
          <name>Medical ethics</name>
        </item>
        <item>
          <name>Medical research</name>
        </item>
        <item>
          <name>Medical supplies</name>
        </item>
        <item>
          <name>Parties to actions</name>
        </item>
        <item>
          <name>Physicians</name>
        </item>
        <item>
          <name>Product safety</name>
        </item>
        <item>
          <name>Products liability</name>
        </item>
        <item>
          <name>Science, Technology, Communications</name>
        </item>
        <item>
          <name>State courts</name>
        </item>
        <item>
          <name>State laws</name>
        </item>
        <item>
          <name>Veterinary medicine</name>
        </item>
        <item>
          <name>Warning labels</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2007-05-10</actionDate>
        <actionDesc>Introduced in House</actionDesc>
        <updateDate>2007-08-08T21:01:07Z</updateDate>
        <text><![CDATA[ <p>Food and Drug Administration Improvement Act of 2007 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to require that all fees collected for the review of applications for human drugs, devices, and animal drugs be deposited in the general fund of the Treasury. Makes available amounts necessary for the Secretary of Health and Human Services to review such applications.</p> <p>Prohibits the Secretary from entering into agreements with persons from whom such fees are collected and terminates any existing agreements.</p> <p>Requires the Secretary to: (1) establish the Center for Postmarket Drug Safety and Effectiveness within the Food and Drug Administration (FDA) to regulate approved drugs; and (2) transfer to the Center all responsibilities for such regulation from the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.</p> <p>Allows the Secretary to require manufacturers of approved drugs to conduct studies of an identified significant safety issue with the drug.</p> <p>Deems a drug to be misbranded if it does not meet the Secretary's requirements, including requirements for labeling and conducting postmarket studies.</p> <p>Requires the Secretary to follow the interpretation that the FDA used in 1999 that the FFDCA and Public Health Service Act establish minimal standards but do not preclude additional state requirements. Requires the Secretary to cease intervening in product liability civil actions to argue another interpretation.</p> <p>Sets forth procedures for advisory committee meetings to ensure that the committee is fairly balanced. Prohibits any exemptions from being granted to advisory committee members from rules prohibiting members from having a personal financial interest in the outcome.</p> <p>Requires doctors to inform patients and obtain consent to prescribe an approved drug for a purpose that has not been approved by the FDA.</p>]]></text>
      </summary>
    </summaries>
    <title>Food and Drug Administration Improvement Act of 2007</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Food and Drug Administration Improvement Act of 2007</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to provide for the deposit in the general fund of the Treasury of fees that are collected from manufacturers of drugs and devices under chapter VII of such Act, to terminate the authority of the Food and Drug Administration to negotiate with the manufacturers on particular uses of the fees, to establish a Center for Postmarket Drug Safety and Effectiveness, to establish additional authorities to ensure the safe and effective use of drugs, and for other purposes.</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Titles as Introduced</titleType>
        <title>Food and Drug Administration Improvement Act of 2007</title>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in House</type>
        <date>2007-05-10T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-110hr2273ih/xml/BILLS-110hr2273ih.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2007-05-10</actionDate>
      <text>Referred to the Subcommittee on Health.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
